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Chronic rhinosinusitis (CRS) is one of the most common 
human conditions, with an estimated prevalence of 12.5%,1 
greater than chronic back pain or diabetes.2 CRS generates 
annual direct health costs in excess $5.8 billion.3 The dis-
ease is often refractory to current pharmacological treat-
ment with antibiotics and corticosteroids,4 leaving many 
patients facing the choice of surgery or persistent symp-
toms. Despite this lack of efficacy, medical treatment has 
demonstrated little change during an era that has seen sig-
nificant innovation in surgical management. However 
effective surgery may now be in the short term, a relatively 
high disease recurrence rate persists.5 The lack of medical 
treatment options is however not surprising given our poor 
understanding of the pathogenesis of CRS. A concerted 
international effort utilizing a variety of methodological 
approaches, including clinical, in vivo, and in vitro cellular 
studies, is being pursued to improve our knowledge of 
chronic rhinosinusits. Within our CRS group we are cur-
rently focused on the association between the sinonasal epi-
thelium and the sub-epithelial fibroblast layer and their 
roles in the persistent CRS inflammatory environment. To 
investigate this further, we have employed both patient-
derived primary cultures of human sinonasal cells isolated 
from patients undergoing sinus operations and also sought 
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Abstract
Background: Well-characterized cell lines represent useful scientific tools to study the pathophysiology of human disease. 
Chronic rhinosinusitis (CRS) is a very common condition, though the number of CRS cell lines is limited, as are data 
showing how closely they resemble primary cells.
Methodology: Searches for available human cell lines were performed using the American Type Culture Collection 
(ATCC) and European Collection of Cell Cultures (ECACC). Identified cells were cultured and characterized with tinctorial 
and immunohistochemical staining and ELISA to assess their response to common, disease-relevant inflammatory stimuli. 
Carefully phenotyped CRS patients were recruited with informed consent. Primary nasal epithelial cell (PNEC) brushings 
were harvested, cultured, and compared to the available cell lines.
Results: Searches identified 1 relevant CRS sino-nasal cell line, RPMI 2650. Cultured PNECs showed strong expression 
of epithelial markers while being negative for mesenchymal markers. However, RPMI 2650 cells show an atypical mixed 
epithelial/mesenchymal phenotype. When stimulated by pro-inflammatory ligands, PNECs responded in a dose-dependent 
manner, whereas RPMI 2650 cells showed limited response.
Conclusions: The number and availability of cell lines to study the pathophysiology of CRS greatly underrepresent the 
disease burden. Additionally, the sole commercially available cell line appears to have a different phenotype and behavior to 
primary patient-derived cells. The development of further reproducible cell lines would be beneficial in our understanding 
of CRS.
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to use immortalized cell lines for their inherent reproduc-
ibility. Cell lines are widely used to interrogate disease 
mechanisms throughout the body and act as rapid, effective 
laboratory models for hypothesis testing without the cellu-
lar heterogeneity or interindividual variability of patient-
derived samples. To our surprise, the number of 
commercially available cell lines to study CRS is very lim-
ited and may not be representative of the parent tissue from 
within the sinonasal cavity.
Materials and Methods
Culture of RPMI 2650 Cells
Searches for commercially available cell lines were per-
formed via the online catalogs of the American Type Culture 
Collection (ATCC) and European Collection of Cell 
Cultures (ECACC) using the search terms nasal, sinus, and 
human. Searches yielded 1 relevant cell line, RPMI 2650, 
which was purchased and grown in standard laboratory cell 
culture conditions. A vial of 2 × 106 cells was cultured as 
per the suppliers instructions (ATCC) in Sigma EMEM 
(M2279, Sigma UK, Dorset, UK) with 1% non-essential 
amino acids (NEAA) (7145, Sigma UK), plus 100 iu/ml 
penicillin/streptomycin (P0781, Sigma UK), 50 ml fetal 
calf serum (FCS) (F9665, Sigma UK), and 2 mM 
L-Glutamine (G7513, Sigma UK). Cells were supplied at 
P26 and were amplified in T75 tissue culture flasks to gen-
erate sufficient cell numbers for our experiments. Cells 
were grown as submerged monolayer cultures in tissue cul-
ture flasks for stimulation experiments and on 13 mm cov-
erslips for imaging.
Culture of Primary Nasal Epithelial Cells
Participants undergoing elective operations for chronic rhi-
nosinusitis according to the EPOS 2012 international con-
sensus document6 were invited to participate in the study, 
with appropriate ethical and research governance approvals 
(UK National Research Ethics Service, REC reference 13/
NE/0099). Primary nasal epithelial cells (PNECs) were har-
vested from the middle meatus by gentle passage with a 
cytology brush. Isolated PNECs were cultured in Lonza 
BEGM cell culture media (Lonza, CC-3171 & CC-4175) 
plus 100 iu/ml penicillin/streptomycin with media changed 
every 2 days until cells reached confluence.
Cellular Staining. Cells grown on 13 mm coverslips were 
fixed in 4% paraformaldehyde for 10 minutes and then 
washed with 1× phosphate buffered saline (PBS). Glycine 
(100 mM) was added to quench any remaining fixative. 
Cells were then permeabilized in 0.1% Triton-X100 (T8787, 
Sigma UK) in 1× PBS for 30 minutes and washed twice in 
PBS-0.2% Tween 20 (P1379, Sigma UK) and once further 
in 1× PBS. Cells were then either stained with H&E to 
assess cellular morphology or using immunocytochemical 
techniques for epithelial and mesenchymal markers. Pri-
mary antibodies were incubated at 4oC overnight (rabbit 
anti-human cytokeratin 17 Abcam Ab53707, Rabbit anti-
human vimentin Abcam Ab92547), followed by fluoro-
phore-conjugated secondary antibody (goat anti-rabbit 
TRITC conjugated Sigma T6778) at 1:100 dilution in 5% 
bovine serum albumin PBS-0.2% Tween 20 incubated for 
90 minutes in the dark. Negative controls were performed 
with secondary only antibodies and matched IgG isotype 
negative controls to identify if there were nonspecific bind-
ing or background autofluorescence. Coverslips were 
mounted on slides with DAPI Vectashield (H1200, Vector 
Labs, Burlingame, California, USA), and images were cap-
tured with a Leica LSM 510 confocal microscope.
Cell Treatments. Monolayers of PNECs and RPMI 2650 
cells approaching confluence were stimulated with CRS 
disease-relevant pro-inflammatory ligands: TNF-α 1 ng/ml, 
5 ng/ml, 10 ng/ml (T0157, Sigma UK); LPS 0.1 µg/ml, 1 
µg/ml, 10 µg/ml (L2630, Sigma UK); Poly I:C 50 µg/ml, a 
synthetic viral analogue (P9582, Sigma UK); and TGF-β 
5ng/ml (T7924, Sigma UK) for 3 and 24 hours to determine 
if the cells were able to mount appropriate inflammatory 
responses. Untreated control cells without inflammatory 
ligands were cultured in parallel. Standard curves were per-
formed as internal controls to ensure reproducibility 
between experiments. All cells were treated with identical 
conditions in triplicate repeats from the same batch of 
inflammatory ligands. Following stimulation, the condi-
tioned media were harvested and the inflammatory response 
measured by the amount of IL-8 released into the culture 
media. Quantification was by ELISA for IL-8 protein as per 




Primary nasal epithelial cells were successfully grown as 
monolayers from participants undergoing surgery for 
CRS. H&E staining of these cells demonstrated a typical 
confluent cell culture monolayer (Figure 1A). Confocal 
microscopy showed that cells stained strongly positive for 
the epithelial marker cytokeratin 17 (CK-17, Figure 2B) 
and negatively for the mesenchymal or fibroblast marker 
vimentin (Figure 2C). In contrast, RPMI 2650 cells dem-
onstrated different growth and cell-surface staining pat-
terns compared to PNECs. RPMI 2650 cells grew in 
clusters and did not form typical epithelial confluent 
monolayers (Figures 1B and 1C). Immunocytochemical 
staining of RPMI 2650 cells showed an appearance that is 
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atypical for epithelial cells, with stronger expression of 
mesenchymal fibroblastic markers (Figure 2 F) than epi-
thelial markers (Figure 2E), which were only faintly 
positive. The immunostaining appearances, similar to the 
growth pattern, are not consistent for an epithelial cell 
line.
Figure 1. H&E stained cells grown in tissue culture conditions. (A) Primary nasal epithelial cells, magnification ×40. (B) RPMI 2650 
cell line, note the growth in clusters and absence of a confluent monolayer, magnification ×20. (C) Magnification ×40.
Figure 2. Fluorescent immunocytochemical images for epithelial and mesenchymal marker expression in primary nasal epithelial 
cells (PNECs) and RPMI 2650 cells. (A) Negative control showing only blue nuclear DAPI staining. (B) Positive PNEC staining with 
TRITC red cytokeratin 17 epithelial marker. (C) Negative mesenchymal PNEC staining with TRITC red vimentin marker. (D) Negative 
control showing only blue nuclear DAPI staining. (E) and (F) show RPMI 2650 cells weak TRITC red cytokeratin 17 epithelial and 
stronger TRITC red vimentin mesenchymal staining, respectively. (G) Positive control staining for cytokeratin 17 with HBE-14 human 
bronchial epithelial cell line. (H) Positive control staining for vimentin with MRC-5 lung fibroblast cell line. Magnification ×63.
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Cell Stimulus Experiments
RPMI 2650 cells were additionally shown to produce very 
little inflammatory response as measured by IL-8 release to 
a range of ligands at 2 different time points. When com-
pared to control untreated cells, tumor necrosis factor-α 
(TNF-α), lipopolysaccharide (LPS), poly I:C, and trans-
forming growth factor-β (TGF-β) stimulated cells did not 
produce the expected inflammatory IL-8 response at either 
3 or 24 hours (Figures 3B and 3D). The number of pico-
grams IL-8 per milliliter detected was very low and never 
exceeded 10 pg/ml. In contrast, when PNECs were sub-
jected to inflammatory stimuli with the CRS-relevant ligand 
TNF-α, they demonstrated a marked dose-dependent 
response, with IL-8 being produced up to 5000 picograms 
per milliliter (Figures 3A and 3C). Similar doses of TNF-α 
showed no response in RPMI 2650 cells.
Discussion
Chronic rhinosinusitis is a very common condition that con-
sumes significant health resources worldwide. There are 
vast direct health expenditures from the medical and surgi-
cal treatments for this condition. The mainstay of medical 
treatment has not changed from corticosteroids and antibi-
otics over many decades, at a time that has seen significant 
advances in the medical management of similar inflamma-
tory conditions. Sinusitis remains the fifth most common 
indication for an antibiotic to be prescribed,7 yet antibiotics 
are not always effective. The position internationally of 
increasing antibiotic resistance and the slow progress in 
developing new antimicrobial agents8 illustrate further the 
unmet need for better CRS treatments. More modern, 
mechanistically focused anti-inflammatory and biological 
medications have been used in other chronic inflammatory 
Figure 3. Amounts of IL-8 cytokine released into cell culture media following stimulation with disease-relevant chronic rhinosinusitis 
(CRS) inflammatory stimuli measured as protein content by ELISA. (A) Three-hour incubation of primary nasal epithelial cells (PNECs). 
(B) Three-hour incubation of RPMI 2650 cells. (C) Twenty-four–hour incubation of PNECs. (d) Twenty-four–hour incubation of RPMI 
2650 cells. UT, untreated media only controls.
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conditions since the end of the twentieth century such as 
anti TNF-α therapy in rheumatoid arthritis9 and inflamma-
tory bowel diseases.10 The prolonged use of corticosteroid 
medications is also not without risk. Although the majority 
of CRS steroid preparations are given topically rather than 
systemically, systemic absorption and suppression of the 
hypothalamo-pituitary axis does occur.11 The development 
of novel anti-inflammatory treatments for rheumatoid 
arthritis and inflammatory bowel diseases has followed 
from a greater understanding of the disease pathophysiol-
ogy.12 Although such conditions are by no means com-
pletely characterized, advances in their detailed knowledge 
has translated into new therapies for patients. In many ways, 
CRS appears to show some similar pro-inflammatory and 
fibrotic disease characteristics,13 though these remain very 
early findings. Hopefully a more detailed understanding of 
the CRS disease mechanisms will lead to similar treatment 
advances for CRS patients.
Cell lines represent very useful laboratory tools to study 
the pathophysiology of human disease. Their use is wide-
spread throughout all organ systems, which is reflected in 
the number and variety of available cell lines. The ECACC 
alone at present holds in excess of 40 000 cell lines avail-
able for study since its establishment in 1984.14 A search of 
the online catalog for ECACC, for example, offers research-
ers investigating pathology for similar inflammatory condi-
tions in the lower airways with 97 possible cell lines 
available.15 Here we have identified only 1 commercially 
available cell line to study CRS, RPMI 2650. Unlike many 
other human conditions, there has been a paucity of well-
validated reliable cellular models to study CRS. The only 
readily available commercial sinonasal cell line RPMI 2650 
is often used in sinonasal studies,16-19 yet there is little pub-
lished data about its relationship to sinonasal cells and its 
validity as a cellular model.
There are of course some shortcomings from the experi-
mental approach that we have utilized to compare patient-
derived PNECs with the sinonasal cell line RPMI 2650. 
First, we have grown both cell types in submerged culture 
rather than at an air-liquid interface to force differentiation. 
We chose this approach as in earlier air-liquid culture exper-
iments we were not able to create a differentiated ciliated 
epithelium with RPMI 2650 cells (S Ball & co-authors, 
unpublished data) in agreement with previous work investi-
gating the use of the cell line in nasal drug delivery stud-
ies.20,21 A major function of cells of the sinonasal cavity is in 
mucociliary clearance, which due to the nature of sub-
merged culture could not be assessed here.
From our investigations we have shown that the sinona-
sal cell line RPMI 2650 is significantly different from 
patient-derived PNECs in terms of its cellular morphology, 
surface marker expression, and biological response to CRS 
disease-relevant inflammatory ligands such as TNF-α.22-25 
While this is initially disappointing, it is perhaps not 
surprising when we investigate the origin of the cell line. It 
was derived from an anaplastic squamous cell carcinoma of 
the nasal septum in a 52-year-old male.26 Tumor cells were 
isolated from his metastatic pleural effusion and shown to 
grow as adherent nasal epithelial cells. The cell line has 
been proven to have a similar diploid karyotype to normal 
nasal epithelial cells.27 It has also been shown to have some 
similarity in terms of the expressed surface cytokeratins,28 
and it produces a mucoid material that is visible on the cells 
apical surface.26 To date, the cell line has only been vali-
dated as a model to study the regulation of TGF-β biology 
in house dust mite–related allergic rhinitis.29 The neoplastic 
source of these cells perhaps explains the mixed epithelial 
and mesenchymal phenotype and growth pattern in cell cul-
ture. As a result, presently we would not recommend the use 
of RPMI 2650 as an in vitro cellular model for the sinonasal 
epithelium in CRS studies. In preference, we would advo-
cate the use of primary, patient-derived nasal epithelial cells 
until such time that better validated sinonasal cell lines are 
established. The unmet disease burden from CRS would no 
doubt benefit from better CRS cell lines to aid our progress 
in understanding and treating this condition.
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